생명과학회지 (Journal of Life Science)

  • 제18권4호
  • /
  • Pages.494-502
  • /
  • 2008
  • /
  • 1225-9918(pISSN)
  • /
  • 2287-3406(eISSN)
한국생명과학회 (Korean Society of Life Science)
권호 표지
DOI QR코드

DOI QR Code

Helicobacter pylori로부터 유래된 항원의 항원성에 관한 연구

Immunotoxicity Study of Separated Antigen from Helicobacter pylori.

  • 박창호 (대구바이오산업지원센터) ;
  • 배만종 (대구한의대학교 한방식품약리학과)
  • 발행 : 2008.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

본 연구에서는 H. pylori의 감염을 예방하고 치료보조제로 사용할 목적으로 포유동물을 통한 피동면역용 항체를 생산하고자 하였다. 따라서 anti-H. pylori 항체를 함유한 면역우유 생산용 백신개발에 기초자료를 얻고자 H. pylori의 면역성과 면역독성에 관한 실험을 수행하였다. 백신을 반복해서 투여했을 때 야기될 수 있는 알레르기 및 과민반응을 예측하고, 페니실린 쇼크와 같은 심각한 부작용 및 독성유발 가능성을 검색하기 위하여 백신의 면역독성을 평가하였다. 전신성 anaphylaxis 쇼크반응의 유무를 평가하기 위해 각 군당 5마리의 guinea pig에 감작투여한 후 최종감작 1주와 2주째에 귀정맥(ear vein)으로 야기항원을 투여하였다. anaphylaxis 쇼크 반응 시험에서 5마리 중 1마리가 양성반응을 나타낸 경우 의약품의 안전성 평가라는 관점에서는 양성으로 판정한다[11]. H. pylori의 WC항원에 대한 1차 및 2차 야기항원 투여 후 전신성 anaphylaxis 쇼크반응에 대한 관찰 결과는 다음과 같다. H. pylori의 WC에 대한 anaphylaxis 쇼크반응은 WC (H) $60\;{\mu}g/100\;{\mu}l$의 항원농도에서 1차, 2차 야기항원 투여 모두 경증의 증상을 나타내었고, WC (L) $20\;{\mu}g/100\;{\mu}l$의 항원농도에서는 아무런 anaphylaxis 쇼크 증상이 관찰되지 않았다. 그리고 crude urease에 대한 anaphylaxis 쇼크반응은 항원농도가 $20\;{\mu}g/100\;{\mu}l$의 urease (L)와 $60\;{\mu}g/100\;{\mu}l$의 urease (H) 모두에서 아무런 증상도 관찰되지 않았다. Guinea pig-rat를 이용한 PCA 시험에서는 WC (H), WC (L), urease (H), urease (L) 투여군 모두에서 양성반응이 나타나지 않았다. 피부감작성 시험에서는 항원농도에 따라 각각 $80\;{\mu}g/100\;{\mu}l$, $40\;{\mu}g/100\;{\mu}l$, $20\;{\mu}g/100\;{\mu}l$, $20\;{\mu}g/100\;{\mu}l$ 일 때 피부이상 증상 즉, 피부 트러블이 발생하지 않는 최고의 항원농도는 $40\;{\mu}g/100\;{\mu}l$인 것으로 관찰되었다. 결론적으로 항원성 시험에서 H. pylori로부터 분리된 urease 항원이 WC 항원보다 면역독성 측면에서 좀 더 안전할 것으로 조사되었다.

The anaphylaxis shock reaction on the whole cells of H. pylori exhibited a symptom of slight illness for the first and second medication of causing antigen at an antigen concentration of WC (H) $60\;{\mu}g/100\;{\mu}l$ for WC (H) and no anaphylaxis shock symptom was observed at an antigen concentration of $20\;{\mu}g/100\;{\mu}l$ for WC (L). In the case of anaphylaxis shock reaction on the crude urease, no symptom was observed at an antigen concentration of $20\;{\mu}g/100\;{\mu}l$ for both urease (L) and urease (H). In the heterologous passive cutaneous anaphylaxis (PCA) test using a guinea pig-rat, no positive reaction was detected in all the medication groups of WC (H), WC (L), urease (H) and urease (L). In the skin sensitization test, it was observed that the best antigen concentration not causing skin disorder at each of $80\;{\mu}g/100\;{\mu}l$, $40\;{\mu}g/100\;{\mu}l$, $20\;{\mu}g/100\;{\mu}l$, and $20\;{\mu}g/100\;{\mu}l$ was $40\;{\mu}g/100\;{\mu}l$.

키워드

참고문헌

  1. Birmingham, N., S. Payankaulam, S. Thanesvorakul, B. Stefura, K. HayGlass and V. Gangur. 2003. An ELISAbased method for measurement of food-specific IgE antibody in mouse serum: an alternative to the passive cutaneous anaphylaxis assay. J. Immunol. Methods 275, 89-98 https://doi.org/10.1016/S0022-1759(03)00008-5
  2. Blanchard, T. G., J. C. Eisenberg and Y. Matsumoto. 2004. Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. Vaccine 22, 888-897 https://doi.org/10.1016/j.vaccine.2003.11.035
  3. Ermak, T. H., P. J. Giannasca, R. Nichols, G. A. Myers, J. Nedrud, R. Weltzin, C. K. Lee, H. Kleanthous and T. P. Monath. 1998. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II- restricted responses. J. Exp. Med. 188, 2277-2288 https://doi.org/10.1084/jem.188.12.2277
  4. Garhart, C. A., R. W. Redline, J. G. Nedrud and S. J. Czinn. 2002. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect. Immun. 3529-3538
  5. Graham, D. Y., H. M. Malaty, D. G. Evans, D. J. Jr Evans, P. D. Klein and E. Adam. 1991. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100, 1495-1501 https://doi.org/10.1016/0016-5085(91)90644-Z
  6. Hayashi, K., T. Ishikawa, T. Yamashita, T. Tajima and K. Nakayama. 2003. Biphasic response of cutaneous blood flow induced by passive cutaneous anaphylaxis in rats. Eur. J. Pharmacol. 482, 305-311 https://doi.org/10.1016/j.ejphar.2003.09.046
  7. Hifumi, E., Y. Yamada and T. Uda. 2006. A catalytic antibody heavy chain HpU-2 degrading its epitope peptide and H. pylori Urease. Immunol. Lett. 103, 68-74 https://doi.org/10.1016/j.imlet.2005.10.016
  8. Hu, L. T. and H. L. Mobley. 1990. Purification and N-Terminal analysis of urease from Helicobacter pylori. Infect. Immun. 58, 992-998
  9. Hunt, R. H. 1996. Eradication of Helicobacter pylori infection. Am. J. Med. 100 (5A) 42S-50S https://doi.org/10.1016/S0002-9343(96)80228-2
  10. IARC working group on the evaluation of carcinogenic risks to humans. 1994. Helicobacter pylori. in: Schistosomes, liver flukes, and Helicobacter pylori: views and expert opinions of IARC working group on the evaluation of carcirogenic risks to humans. Lyon: IARC Monogr Eval Carcinog Risks Hum. 61-241
  11. Jo, E. H., S. D. Cho, N. S. Ahn, J. W.Jung, S. R. Yang, J. S. Park, K. S. Park, I. S. Hong, M. S. Seo, N. B. Tiep, Y. S. Lee and K. S. Kang. 2003. Antigenicity study of nonspecific immunostimulator $BARODON^{{\circledR}}$. Kor. J. Vet. Res. 43, 255-261
  12. Justine, S. G., E. C. Natalie and H. S. Dieter. 1980. Methods in immunology, a laboratory text for instruction and research. W. A. Benjamin, Inc, Canada
  13. Kim, B. J., B. H. Kang, T. Y. Kim, T. H. Kim and K. W. Kim. 1997. Production and characterization of IgY specific to Helicobacter pylori. Kor. J. Appl. Microbiol. Biotechnol. 25, 612-616
  14. Lee, D. H. 2002. Current status and treatment of Helicobacter pyri infection in korea. Kor. J. Gastrol. 39, 153-160
  15. Lesley, E., M. J. Smythies, K. B. Novak, J. Waites, L. Russell, D. M. Casey and D. S. Phillip. 2005. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine 23, 901-909 https://doi.org/10.1016/j.vaccine.2004.07.037
  16. Mabe, K., M. Yamada, I. Oguni and T. Takahashi. 1999. In vitro and in vivo activities of tea catechins against Helicobacter pylori. Antimicrob Agents Chemother. 43, 1788-1791
  17. Marshall, B. J. and J. R. Warren. 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 323, 1311-1315 https://doi.org/10.1016/S0140-6736(84)91816-6
  18. Megraud, F. 1998. Antibiotic resistance in Helicobacter pylori infection. Br. Med. Bull. 24, 207-216
  19. Michetti, P., I. Corthésy-Theulaz, C. Davin, R. Haas, A. C. Vaney, M. Heitz, J. Bille, J. P. Kraehenbuhl, E. Saraga and A. L. Blum. 1994. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 107, 1002-1011 https://doi.org/10.1016/0016-5085(94)90224-0
  20. Parsonnet, J., R. A. Harris, H. M. Hack and D. K. Owens. 1996. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer; A mandate for clinical trials. Lancet 348, 150-154 https://doi.org/10.1016/S0140-6736(96)01501-2
  21. Ruggiero, P., P. Samuele, R. Rino and D. G. Giuseppe. 2003. The quest for a vaccine against Helicobacter pylori: How to move from mouse to man? Micro. Infec. 5, 749-756 https://doi.org/10.1016/S1286-4579(03)00125-4
  22. Rupnow, M. F., D. K. Owens, R. Shachter and J. Parsonnet. 1999. Helicobacter pylori vaccine development and use: A cost-effectiveness analysis using the institute of Medicine methodology. Helicobacter 4, 272-280 https://doi.org/10.1046/j.1523-5378.1999.99311.x
  23. Rupnow, M. F., R. D. Shachter, D. K. Owens and J. Parsonnet. 2001. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 20, 879-885 https://doi.org/10.1016/S0264-410X(01)00401-7
  24. Satoh, K., K. Kimura and Y. Taniguchi. 1996. Distribution of inflammation and atrophy in the stomach of Helicobacter pylori-positive and -negative patients with chronic gastritis. Am. J. Gastroenterol 91, 963-969
  25. Simon, P. M., P. L. Goode, A. Mobasseri and D. Zopf. 1997. Inhibition of Helicobacter pylori binding to gastrointestinal infect. Immun. 65, 750-757
  26. Warren, J. R. and B. Marshall. 1983. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 4, 1273-1275